Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20856386 | 1.00 | TSHR (0.36) | TSHRLTA4HALDH1A1CA4MAOB | |
| SCHEMBL20856387 | 1.00 | TSHR (0.36) | TSHRLTA4HALDH1A1CA4MAOB | |
| SCHEMBL20856848 | 0.88 | PIM1 (0.31) | — | |
| SCHEMBL20856846 | 0.88 | PIM1 (0.31) | — | |
| SCHEMBL2818333 | 0.77 | LTA4H (0.50) | TSHRLTA4HALDH1A1CA4MAOB | |
| SCHEMBL16782647 | 0.77 | LTA4H (0.50) | TSHRLTA4HALDH1A1CA4MAOB | |
| SCHEMBL2818335 | 0.77 | LTA4H (0.50) | TSHRLTA4HALDH1A1CA4MAOB | |
| SCHEMBL3630500 | 0.76 | LTA4H (0.39) | TSHRLTA4HALDH1A1CA4MAOB | |
| SCHEMBL7658790 | 0.76 | TSHR (0.35) | TSHRLTA4HALDH1A1CA4MAOB | |
| SCHEMBL28616418 | 0.73 | LTA4H (0.41) | TSHRLTA4HALDH1A1CA4MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283351-A1 | HALOGENATED HETEROALKENYL- AND HETEROALKYL-FUNCTIONALIZED ORGANIC COMPOUNDS AND METHODS FOR PREPARING SUCH COMPOUNDS | ARKEMA INC. | 2020-09-10 | — | — | US | disclosed |
| WO-2019067394-A1 | HALOGENATED HETEROALKENYL- AND HETEROALKYL-FUNCTIONALIZED ORGANIC COMPOUNDS AND METHODS FOR PREPARING SUCH COMPOUNDS | ARKEMA INC. (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283351-A1 | HALOGENATED HETEROALKENYL- AND HETEROALKYL-FUNCTIONALIZED ORGANIC COMPOUNDS AND METHODS FOR PREPARING SUCH COMPOUNDS | SOAT2, SOAT1, PNMT | TSHR 1023/4885LTA4H 1545/4885ALDH1A1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.